NASDAQ · TRAW
Healthcare · Biotechnology
$0.30
Up+$0.00 (+0.57%)
Updated Nov 4, 2026, 10:38 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TRAW
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
TRAW closed at $0.30 after 21 trading sessions, down 41.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.30 | $0.3139 | $0.30 | $0.302 | 63.73K |
| Nov 2, 2026 | $0.31 | $0.31 | $0.298 | $0.3003 | 70.37K |
| Oct 30, 2026 | $0.3098 | $0.3098 | $0.2876 | $0.296 | 199.52K |
| Oct 29, 2026 | $0.37 | $0.37 | $0.30 | $0.301 | 718.98K |
| Oct 28, 2026 | $0.363 | $0.363 | $0.3201 | $0.3598 | 28.58K |
| Oct 27, 2026 | $0.3412 | $0.366 | $0.31 | $0.366 | 150.58K |
| Oct 26, 2026 | $0.367 | $0.368 | $0.332 | $0.3411 | 37.54K |
| Oct 23, 2026 | $0.351 | $0.351 | $0.3311 | $0.3425 | 110.67K |
| Oct 22, 2026 | $0.3718 | $0.3847 | $0.3618 | $0.3667 | 62.22K |
| Oct 21, 2026 | $0.3845 | $0.387 | $0.3682 | $0.376 | 84.46K |
| Oct 20, 2026 | $0.3849 | $0.3854 | $0.3673 | $0.3767 | 93.13K |
| Oct 19, 2026 | $0.389 | $0.3892 | $0.3601 | $0.3665 | 99K |
| Oct 16, 2026 | $0.4137 | $0.4137 | $0.3621 | $0.3693 | 257.69K |
| Oct 15, 2026 | $0.40 | $0.4144 | $0.391 | $0.4031 | 45.95K |
| Oct 14, 2026 | $0.41 | $0.4175 | $0.3921 | $0.4012 | 150.37K |
| Oct 13, 2026 | $0.4223 | $0.43 | $0.407 | $0.4101 | 93.88K |
| Oct 12, 2026 | $0.43 | $0.4444 | $0.41 | $0.416 | 178.37K |
| Oct 9, 2026 | $0.4671 | $0.4731 | $0.4337 | $0.4452 | 689.93K |
| Oct 8, 2026 | $0.4791 | $0.4815 | $0.4621 | $0.4803 | 199.71K |
| Oct 7, 2026 | $0.52 | $0.52 | $0.4608 | $0.479 | 221.84K |
| Oct 6, 2026 | $0.5345 | $0.535 | $0.5183 | $0.52 | 125.05K |
The latest Smart Investors Daily articles mentioning TRAW.
Company
Market Activity
Research & News
TRAW research
Company profile and research snapshot.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 15, 2026 | Ladenburg Thalmann | Neutral | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 3, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 26, 2026
Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments" or the
Benzinga · Oct 23, 2026
-SEC Filing
Benzinga · Aug 18, 2026
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.
Benzinga · Aug 14, 2026
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRAW.
